title: Reply: To PMID 22967868.
authors.forename: Sheng-Fu
authors.initials: SF
authors.lastname: Cheng
authors.forename: Mohammad H
authors.initials: MH
authors.lastname: Dastjerdi
authors.forename: Giulio
authors.initials: G
authors.lastname: Ferrari
authors.forename: Andre
authors.initials: A
authors.lastname: Okanobo
authors.forename: Francisco
authors.initials: F
authors.lastname: Amparo
authors.forename: William
authors.initials: W
authors.lastname: Stevenson
authors.forename: Pedram
authors.initials: P
authors.lastname: Hamrah
authors.forename: Nambi
authors.initials: N
authors.lastname: Nallasamy
authors.forename: Reza
authors.initials: R
authors.lastname: Dana
authors.forename: Kraig S
authors.initials: KS
authors.lastname: Bower
authors.forename: Denise S
authors.initials: DS
authors.lastname: Ryan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D016510:Corneal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized